The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Cannabinoids and the gastrointestinal tract
Open accessAbstract
The enteric nervous system of several species, including the mouse, rat, guinea pig and humans, contains cannabinoid CB 1 receptors that depress gastrointestinal motility, mainly by inhibiting ongoing contractile transmitter release. Signs of this depressant effect are, in the whole organism, delayed gastric emptying and inhibition of the transit of non-absorbable markers through the small intestine and, in isolated strips of ileal tissue, inhibition of evoked acetylcholine release, peristalsis, and cholinergic and non-adrenergic non-cholinergic (NANC) contractions of longitudinal or circular smooth muscle. These are contractions evoked electrically or by agents that are thought to stimulate contractile transmitter release either in tissue taken from morphine pretreated animals (naloxone) or in unpretreated tissue (γ-aminobutyric acid and 5-hydroxytryptamine). The inhibitory effects of cannabinoid receptor agonists on gastric emptying and intestinal transit are mediated to some extent by CB 1 receptors in the brain as well as by enteric CB 1 receptors. Gastric acid secretion is also inhibited in response to CB 1 receptor activation, although the detailed underlying mechanism has yet to be elucidated. Cannabinoid receptor agonists delay gastric emptying in humans as well as in rodents and probably also inhibit human gastric acid secretion. Cannabinoid pretreatment induces tolerance to the inhibitory effects of cannabinoid receptor agonists on gastrointestinal motility. Findings that the CB 1 selective antagonist/inverse agonist SR141716A produces in vivo and in vitro signs of increased motility of rodent small intestine probably reflect the presence in the enteric nervous system of a population of CB 1 receptors that are precoupled to their effector mechanisms. SR141716A has been reported not to behave in this manner in the myenteric plexus-longitudinal muscle preparation (MPLM) of human ileum unless this has first been rendered cannabinoid tolerant. Nor has it been found to induce “withdrawal” contractions in cannabinoid tolerant guinea pig ileal MPLM. Further research is required to investigate the role both of endogenous cannabinoid receptor agonists and of non-CB 1 cannabinoid receptors in the gastrointestinal tract. The extent to which the effects on gastrointestinal function of cannabinoid receptor agonists or antagonists/inverse agonists can be exploited therapeutically has yet to be investigated as has the extent to which these drugs can provoke unwanted effects in the gastrointestinal tract when used for other therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“It is also noteworthy that the endocannabinoid 2-AG was first isolated from canine small intestine.”
BackgroundSelf-citationSR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Pharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Self-citationCannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Self-citationEndocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanuš, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 571
Self-citationPharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Self-citationAnandamide Amidohydrolase Activity in Rat Brain Microsomes
Desarnaud, F., Cadas, H., & Piomelli, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6030 · Cited by 336
An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing
Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Fur, G. L., Caput, D., & Ferrara, P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.8.3726 · Cited by 330
Lynn, A. B., & Herkenham, M. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38654-4 · Cited by 276
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Distribution of cannabinoid receptors in the central and peripheral nervous system
Mackie, K. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_10 · Cited by 744
History of Cannabis and Its Preparations in Saga, Science, and Sobriquet
Russo, E. B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790144 · Cited by 621
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
“Functional CB1 receptor has been shown to be expressed in the human ileum and colon and the number of CB1-expressing cells was found to be significantly increased after inflammation [59,60].”
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
The endogenous cannabinoid system protects against colonic inflammation
Massa, F., Marsicano, G., Hermann, H., Cannich, A., Monory, K., Cravatt, B. F., Ferri, G.-L., Sibaev, A., Storr, M., & Lutz, B. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19465 · Cited by 460
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
Pertwee, R. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444
Self-citationCannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Cannabinoid Hyperemesis Syndrome
A. Galli, J., Andari Sawaya, R., & K. Friedenberg, F. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104040241 · Cited by 303
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0667-2 · Cited by 294
Pre‐operative fasting guidelines: an update
Søreide, E., Eriksson, L. I., Hirlekar, G., Eriksson, H., Henneberg, S. W., Sandin, R., Raeder, J., & (Task Force on Scandinavian Pre‐operative Fasting Guidelines, C. P. C. S. S. O. A. A. I. C. M. (2005) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2005.00781.x · Cited by 270
Regulation of nausea and vomiting by cannabinoids
Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01176.x · Cited by 268
Wright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
Cannabinoid tolerance and dependence: A review of studies in laboratory animals
GONZALEZ, S., CEBEIRA, M., & FERNANDEZRUIZ, J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.028 · Cited by 258
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Auh, Q.-S., Chun, Y. H., Melemedjian, O. K., Zhang, Y., & Ro, J. Y. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.07.009 · Cited by 14
Metadata
- Authors
- PERTWEE, R. G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-06-01
- Volume
- 48
- Issue
- 6
- Pages
- 859-867
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2157518435
- Cited by
- 326
- References
- 68
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.